JHL Biotech (TWEM: 6540) was founded in 2012 with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation. To achieve this vision, JHL will provide world-class process development and manufacturing services in Asia to companies developing and commercializing high-quality, affordable biologic medicines. JHL is leveraging the latest process and engineering technologies to reduce the complexity and cost of mammalian cell culture manufacturing. These technologies will be incorporated into world-class biologics API manufacturing facilities in Asia that comply with US, EU and ICH cGMP regulations and guidelines.

Led by an experienced team of Genentech and Amgen veterans, and funded by top-tier venture capital firms including Kleiner Perkins Caufield & Byers (KPCB), Sequoia Capital, Biomark Capital and CDIB, JHL is uniquely positioned to deliver manufacturing solutions to its worldwide partners.